QLT Announces Positive Preliminary Results From Phase 1b Trial of QLT091001 in Subjects With Retinitis Pigmentosa Due to RPE65 and LRAT Mutations

Loading...
Loading...
QLT Inc.
QLTI
today announced positive preliminary results from its international multi-center Phase 1b proof-of-concept clinical trial of QLT091001 for the treatment of Retinitis Pigmentosa (
RP
) due to inherited genetic mutations in retinal pigment epithelium protein 65 (RPE65) or lecithin:retinol acyltransferase. The Phase 1b study showed rapid, statistically significant and clinically meaningful changes in visual fields from baseline values, as well as improvements in visual acuity, in the study of 17 RP subjects. In addition, small subsets of RP subjects were investigated for secondary effects on other key vision parameters impacted by RP, such as decreased retinal sensitivity, and the data available in these subsets showed notable and promising increases in average sensitivity levels. The single-course treatment data with QLT091001 represents the first stage of dose regimen testing as the basis for a longer term multiple course regimen in RP due to mutations in RPE65 and LRAT.
Posted In: NewsFDA
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...